FDA OKs New Therapy for Some Hemophilia Patients - NBC4 Washington
National & International News
The day’s top national and international news

FDA OKs New Therapy for Some Hemophilia Patients

Genentech, the drug's developer, says the list price will be about $482,000 for the first year and slightly less after that

    processing...

    NEWSLETTERS

    Sentara Helps Army Vet Take Control of Her Pain
    AP/Genentech, Inc.
    This photo provided by Genentech, Inc. shows a package of the drug Hemlibra. On Thursday, Nov. 16, 2017, the Food and Drug Administration approved Hemlibra, the first new treatment in nearly two decades to prevent internal bleeding in certain patients with hemophilia, an inherited blood-clotting disorder.

    U.S. regulators have approved the first new treatment in nearly two decades to prevent internal bleeding in certain patients with hemophilia, an inherited blood-clotting disorder.

    The Food and Drug Administration on Thursday approved Hemlibra (hem-LEE'-bruh), a weekly injection for hemophilia A patients who have developed resistance to standard medicines.

    Genentech, the drug's developer, says the list price will be about $482,000 for the first year and slightly less after that.

    Genentech, a subsidiary of Swiss drugmaker Roche, says that's half the cost of the only other option for patients with this resistance. That treatment requires an IV drip several times a week.

    Survivor of Santa Fe HS Shooting: 'I Was Scared for My Life'

    [NATL] Survivor of Santa Fe High School Shooting: 'I Was Scared for My Life'

    Dakota Shrader, a student from Santa Fe High School, describes what happened when shots were fired during her morning history class. Multiple people died during the shooting.

    (Published Friday, May 18, 2018)

    Hemophilia mostly affects males.